{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"71","upperLimit":"89","value":"79"},{"groupId":"OG001","lowerLimit":"80","upperLimit":"95","value":"87"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"159"},{"groupId":"OG001","value":"154"}],"units":"Participants"}],"description":"Overall survival (OS) is measured from date of randomization to date of death due to any cause. Participants known to be alive are censored at date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Within 17 days (preferably within 14 days) days after IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 18 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood throughout the study and MRI or CT on study.\n\nBiospecimen Collection: Undergo collection of blood\n\nComputed Tomography: Undergo CT\n\nMagnetic Resonance Imaging: Undergo MRI\n\nPembrolizumab: Given IV\n\nTherapeutic Conventional Surgery: Undergo surgery","id":"OG000","title":"Arm I (Adjuvant Pembrolizumab)"},{"description":"Patients receive pembrolizumab IV over 30 minutes on day 1 every 3 weeks for 3 cycles, then undergo surgery within 3 weeks. Within 84 days, patients receive pembrolizumab IV over 30 minutes every 3 weeks for 15 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood throughout the study and MRI or CT on study.\n\nBiospecimen Collection: Undergo collection of blood\n\nComputed Tomography: Undergo CT\n\nMagnetic Resonance Imaging: Undergo MRI\n\nPembrolizumab: Given IV\n\nTherapeutic Conventional Surgery: Undergo surgery","id":"OG001","title":"Arm II (Adjuvant and Neoadjuvant Pembrolizumab)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 years","title":"Two-Year Overall Survival Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}